Children’s National Hospital announces licensing agreement with MGeneRx Inc. for proprietary biometric analysis technology
Childrens National Hospital announces that it has entered into a licensing agreement with MGeneRx Inc. for its patented pediatric medical device technology using objective digital biometric analysis software for the early and non-invasive screening of dysmorphic genetic diseases.
- Childrens National Hospital announces that it has entered into a licensing agreement with MGeneRx Inc. for its patented pediatric medical device technology using objective digital biometric analysis software for the early and non-invasive screening of dysmorphic genetic diseases.
- The objective digital biometric analysis technology was developed by a multidisciplinary Childrens National team led by Marius George Linguraru, D.Phil, M.A., M.Sc.
- , of the Sheikh Zayed Institute for Pediatric Surgical Innovation and Marshall Summar, M.D ., director of the Childrens National Rare Disease Institute (CNRDI).
- Childrens National is home to the Childrens National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation and is the nations seventh-highest NIH-funded childrens hospital.